Uveitis and Papillitis in the Setting of Dabrafenib and Trametinib Therapy for Metastatic Melanoma: A Case Report. (19th May 2018)

• Record Type: Journal Article
• Authors: Lim, Jennifer; Lomax, Anna J.; McNeil, Catriona; Harrisberg, Brian
• Is Part Of: Ocular immunology and inflammation. Volume 26:Number 4(2018)
• Page Start: 628
• Page End: 631
• Publication Date: 2018-05-19
• Subjects: BRAF/MEK inhibitor -- dabrafenib -- ocular toxicity -- papillitis -- trametinib; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.1080/09273948.2016.1246666
• Languages: English
• ISSNs: 0927-3948

Abstract

ABSTRACT: Purpose : To report the diagnosis of acute VKH-like syndrome as a complication from dabrafenib (a serine/threonine inhibitor of BRAF V600 ) and trametinib (a MEK inhibitor). In combination, these targeted agents have been shown to prolong overall survival and progression free survival in BRAF mutant metastatic melanoma. Methods : Retrospective medical chart review including radiologic and ophthalmologic investigations. Results : A patient with metastatic melanoma being treated with dabrafenib and trametinib for 2 months presented with 1 week of visual blurring. He had developed bilateral optic disc swelling and uveitis that responded to pulsed steroid therapy. Conclusions : VKH-like syndrome is a rare but serious complication of targeted therapy that should be considered when evaluating a patient with visual disturbances on dabrafenib and trametinib therapy.